DURHAM,
N.C., Aug. 28, 2024 /PRNewswire/ -- EydisBio, an
early-stage pharmaceutical company leveraging a novel approach to
treating various autoimmune and inflammatory diseases, is thrilled
to announce that it has been awarded a $2.6
million Phase 2 Small Business Innovation Research (SBIR)
grant from the National Institute of Health's (NIH) National Heart,
Lung, and Blood Institute (NHLBI). This grant will further support
EydisBio's ongoing research into the efficacy of TAK1 inhibition in
animal models of systemic sclerosis and declare a lead
compound for progression into the clinic.
"We are honored to receive this significant grant from the
NHLBI," said Dr. Tim Haystead,
Founder and President of EydisBio. "This funding will enable us to
continue to advance our TAK1 inhibitor program in systemic
sclerosis and bring us closer to developing a new therapeutic
option for these patients. We are strongly committed to improving
the lives of those affected by this debilitating disease."
Systemic sclerosis, also known as scleroderma, is a rare chronic
autoimmune disease characterized by hardening and tightening of the
skin and connective tissues. It can also affect internal organs,
leading to severe complications. Current treatments focus on
managing symptoms and slowing disease progression, mainly for
patients with systemic sclerosis-associated interstitial lung
disease (SSc-ILD), but clinical benefit is highly limited and there
is no cure. Moreover, no novel therapies have been approved for
addressing manifestations beyond SSc-ILD, all of which highlights a
critical unmet need across the entire systemic sclerosis disease
spectrum.
Aberrant TAK1 signaling plays a pivotal role in the
pathophysiological cycle of inflammation, fibrosis, and
vasculopathy that drives systemic sclerosis, and inhibition of this
pathway represents a novel therapeutic strategy. EydisBio's TAK1
inhibitors have demonstrated significant promise in recent
preclinical studies involving fibroblasts derived from systemic
sclerosis patients and a bleomycin-induced mouse model of the
disease. This project will support continued analog development to
identify a highly effective and safe lead compound and further
investigate its potential for treating SSc-ILD and related
manifestations. Following this, EydisBio will undertake
GLP-compliant toxicity studies to support the advancement of the
program through Investigational New Drug (IND) filing and into
clinical trials.
For more information about EydisBio and their groundbreaking
research, please visit www.eydisbio.com.
Media Contact:
Robert Freeze
info@eyedisbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eydisbio-awarded-2-6-million-grant-to-advance-tak1-inhibitor-program-for-systemic-sclerosis-302231898.html
SOURCE EydisBio, Inc.